Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:MDXXF)

0.1152 +0.0062 (+5.69%)
Streaming Delayed Price Updated: 2:13 PM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MDXXF

News headline image
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
Definitive Agreement Targeted for Execution by June 2026 
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
Company Advances Next-generation Patented MDMA Toward Patient Dosing in 2026 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Cortexa Advances Commercialisation of MDMA Supply in Australia
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
From PharmAla Biotech
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Contracts with Partner to Act as US Distributor
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Launches MDMA Clinical Trial Tool for Researchers
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
From PharmAla Biotech
Via GlobeNewswire
News headline image
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market 
From PharmAla Biotech
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.